human
diseas
affect
upper
andor
lower
part
respiratori
tract
associ
high
morbid
socioeconom
burden
diseas
rang
chronic
condit
asthma
chronic
obstruct
pulmonari
diseas
acut
infect
bacteri
viral
etiolog
signific
number
respiratori
infect
caus
virus
respiratori
syncyti
viru
rsv
account
annual
death
worldwid
influenza
virus
account
season
flu
epidem
death
yearli
har
natur
process
rna
interfer
rnai
silenc
downregul
specif
gene
present
excit
therapeut
strategi
acut
viral
infect
ideal
candid
due
suscept
shortterm
treatment
facilit
transient
natur
rnai
activ
addit
target
conserv
viral
gene
cellular
host
factor
reduc
resist
consequ
viral
genet
evolut
exampl
found
influenza
requir
season
vaccin
furthermor
rnaibas
drug
offer
possibl
simultan
silenc
sever
viral
andor
host
gene
involv
pathogenesi
may
improv
therapeut
effect
local
applic
respiratori
mucosa
repres
attract
altern
intraven
inject
avoid
necess
overcom
serum
nucleas
degrad
nonspecif
accumul
rapid
renal
clearanc
effect
respiratori
rnai
therapeut
howev
depend
overcom
anatom
mucu
cellular
barrier
restrict
deliveri
uptak
molecul
across
epithelium
review
describ
current
statu
rnaibas
treatment
respiratori
diseas
focu
preclin
studi
clinic
trial
use
synthet
sirna
sirna
attent
given
overcom
biolog
physiolog
barrier
diseas
rnai
target
select
safe
sirna
design
essenti
requir
realiz
clinic
potenti
rnaibas
therapeut
fig
discoveri
rnai
mediat
doublestrand
rna
dsrna
molecul
act
potent
rnai
trigger
mammalian
cell
pave
way
toward
clinic
translat
rnaibas
therapeut
rnai
constitut
fundament
process
eukaryot
organ
allow
select
gene
silenc
transcript
posttranscript
level
serv
defens
mechan
viral
infect
well
transposon
mobil
genet
element
addit
involv
finetun
regul
cellular
gene
express
higher
eukaryot
mediat
posttranscript
gene
silenc
process
nucleotid
length
dsrna
upon
incorpor
rnainduc
silenc
complex
risc
direct
cleavag
destabil
translat
repress
target
messeng
rna
mrna
activ
direct
partial
complet
base
pare
guid
strand
retain
activ
risc
target
mrna
synthet
sirna
engag
pathway
directli
level
risc
longer
dsrna
speci
exampl
viral
origin
requir
previou
process
cytoplasm
rnase
iii
enzym
dicer
rnai
activ
also
mediat
endogen
small
noncod
rna
known
microrna
mirna
control
cellular
gene
express
effector
molecul
normal
transcrib
rna
polymeras
ii
long
primari
mirna
primirna
subsequ
process
enzym
drosha
nt
stemloop
structur
term
precursor
mirna
premirna
transport
cytoplasm
premirna
cleavag
dicer
nt
rna
duplex
incorpor
risc
contrast
sirna
direct
mrna
cleavag
perfect
guid
strandmrna
complementar
matur
mirna
incorpor
risc
induc
translat
repress
partial
anneal
mrna
untransl
region
utr
consider
effort
attempt
har
exogen
endogen
branch
rnai
pathway
therapeut
purpos
exampl
therapeut
intervent
may
aim
regul
mirna
activ
mirna
inhibitor
term
antagomir
way
inhibit
tumor
progress
restor
express
mirna
exhibit
antitumor
activ
despit
excit
posibl
mirna
pathway
major
effort
develop
rnai
therapeut
focus
engag
exogen
rnai
pathway
sirna
effector
molecul
normal
deliv
directli
cellular
cytoplasm
requir
case
socal
dicer
substrat
shorter
sirna
enzymat
cleavag
risc
incorpor
altern
trigger
translat
intracellularli
plasmid
viral
rector
pri
premirnalik
structur
would
analog
endogen
mirna
becom
process
load
risc
influenza
virus
contain
segment
genom
compos
eight
singlestrand
rna
molecul
neg
polar
classifi
type
b
c
rna
virus
capabl
overcom
interspeci
barrier
therefor
circul
amongst
variou
anim
host
influenza
viru
import
implic
human
diseas
respons
epidem
occasion
pandem
season
flu
year
caus
death
thousand
peopl
common
practic
control
iav
infect
season
vaccin
treatment
antivir
compound
adamant
deriv
neuraminidas
inhibitor
sever
preclin
studi
evalu
sirnamedi
silenc
viral
protein
nucleoprotein
compon
rna
polymeras
abolish
replic
addit
recent
genomewid
screen
identifi
host
factor
involv
iav
infect
contrast
studi
system
employ
karla
et
al
allow
identif
host
factor
involv
earli
midstag
also
late
phase
infect
fortyeight
hour
posttransfect
sirna
commerci
avail
librari
human
lung
epitheli
cell
line
challeng
influenza
viru
viral
infect
monitor
either
directli
cell
stain
virusspecif
antibodi
bioluminesc
ad
viruscontain
supernat
cell
onto
human
embryon
kidney
report
cell
line
data
suggest
primari
hit
gene
affect
viru
replic
valid
analysi
employ
influenza
strain
main
conclus
work
involv
valid
hit
earli
stage
iav
infect
mani
essenti
broad
spectrum
influenza
virus
make
conceiv
sirna
design
broad
spectrum
antivir
activ
interestingli
limit
number
gene
overlap
among
differ
studi
probabl
consequ
differ
experiment
set
employ
rsv
singlestrand
negativesens
rna
viru
common
infect
affect
respiratori
tract
mild
symptom
character
coldlik
symptom
occur
healthi
adult
older
children
howev
major
caus
hospit
viral
death
infant
individu
suffer
chronic
lung
diseas
compromis
immun
system
similarli
elderli
peopl
adult
underli
lung
patholog
pneumonia
asthma
chronic
obstruct
pulmonari
diseas
rsv
induc
sever
respiratori
complic
affect
lower
respiratori
tract
accept
rsv
antivir
intervent
present
treatment
inhal
ribavirin
prophylact
administr
human
monoclon
antibodi
viral
fusion
protein
usag
ribavirin
restrict
due
question
efficaci
potenti
seriou
side
effect
prophylact
treatment
mainli
limit
infant
high
risk
rsv
infect
recent
year
rnaibas
preclin
studi
focus
silenc
viral
phosphoprotein
nonstructur
protein
reduc
infect
significantli
sever
clinic
trial
conduct
determin
safeti
antivir
activ
sirna
viral
nprotein
refer
rsv
clinic
program
coronavirus
envelop
virus
posit
singlestrand
rna
ssrna
genom
anim
caus
lifethreaten
diseas
affect
respiratori
tract
system
organ
identif
caus
sar
epidem
two
coronaviru
strain
known
infect
human
recogn
caus
agent
approxim
case
common
cold
although
coronavirus
normal
affect
upper
respiratori
tract
also
caus
lower
respiratori
tract
diseas
immunecompromis
patient
person
underli
lung
patholog
condit
due
devast
consequ
outbreak
signific
effort
made
identif
new
antivir
agent
includ
sirnabas
drug
target
lead
sequenc
spike
proteincod
region
viru
main
target
site
within
respiratori
tract
depend
diseas
type
diseas
sinus
rhinit
common
cold
caus
rhinoviru
predomin
nasal
restrict
rsv
influenza
occur
within
epitheli
cell
upper
lower
respiratori
tract
overcom
barrier
restrict
access
epitheli
cellular
target
crucial
enabl
rnaibas
therapeut
intervent
barrier
divid
nasal
lung
architectur
featur
overli
mucu
epitheli
cell
type
resid
phagocyt
primari
function
nasal
caviti
air
condit
warm
humidifi
air
exterior
bodi
addit
also
function
filter
remov
particul
inhal
air
physiolog
structur
nasal
caviti
support
function
nasal
vestibul
constitut
caviti
nostril
inferior
turbin
follow
nasal
passag
reach
anterior
end
turbin
nasopharynx
cellular
level
epithelia
undergo
chang
squamou
epithelia
vestibul
ciliat
epithelia
turbin
turbin
epitheli
line
consist
tightli
pack
columnar
secretori
epithelia
similar
rest
conduct
airway
present
barrier
sirna
deliveri
architectur
lung
divid
two
main
function
region
trachea
bronchi
bronchiol
commonli
term
airway
air
sac
alveoli
form
ga
exchang
compon
surfac
area
alveoli
much
greater
compar
airway
squar
meter
allow
extens
absorpt
oxygen
despit
favor
anatom
physiolog
condit
increas
bioavail
therapeut
lung
larg
surfac
area
limit
metabol
capac
thin
alveolar
epithelium
extens
blood
suppli
sever
barrier
overcom
success
deliveri
sirna
therapeut
due
extens
amount
bifurc
airway
bifurc
alveoli
deposit
therapeut
deep
lung
challeng
pulmonari
epithelium
airway
compos
pseudostratifi
columnar
layer
secretori
cell
ciliat
cell
togeth
constitut
mucociliari
escal
secretori
cell
divid
goblet
cell
clara
cell
serou
cell
togeth
produc
mucin
antimicrobi
immunomodul
protect
molecul
airway
narrow
proxim
distal
part
height
mucos
line
decreas
cellular
composit
remain
reach
alveoli
epithelia
alveoli
differ
drastic
epithelia
airway
popul
mainli
type
pneumocyt
cell
broad
thin
compar
columnar
cell
airway
epithelia
addit
type
pneumocyt
progenitor
cell
type
cell
surfact
produc
type
pneumocyt
found
alveolar
sac
integr
pulmonari
epithelia
support
tight
junction
epitheli
cell
densiti
tight
junction
airway
five
time
higher
alveoli
special
alveolar
macrophag
present
apic
side
alveoli
assist
remov
foreign
particul
deposit
deep
lung
may
restrict
use
nanoparticl
deliveri
system
local
deliveri
rnai
therapeut
howev
suggest
alveolar
macrophag
transport
foreign
materi
drain
lymph
lung
recent
moscho
et
al
demonstr
nake
lock
nucleic
acid
antisens
oligonucleotid
phosphorothio
backbon
retain
macrophag
intratrach
administr
interestingli
oligonucleotid
shown
migrat
system
site
induc
knockdown
liver
collect
result
suggest
local
pulmonari
administr
may
offer
opportun
dissemin
rnai
therapeut
system
tissu
within
migratori
alveolar
macrophag
overli
epitheli
barrier
nasal
region
airway
fluid
layer
compos
thin
periciliari
liquid
layer
surround
cilia
gel
form
layer
mucu
mucu
hydrat
protein
gel
overlay
lumin
surfac
mucos
site
serv
barrier
extern
environ
underli
tissu
line
respiratori
surfac
serv
first
line
defens
variou
pathogen
toxin
addit
facilit
continu
exchang
gase
mucu
macroscop
properti
gel
exhibit
nonnewtonian
rheolog
behavior
compos
ion
glycoprotein
term
mucin
protein
lipid
dna
cellular
debri
mucin
extend
mda
molecul
produc
secret
goblet
cell
predominantli
found
submucos
gland
larger
airway
healthi
individu
composit
airway
mucu
water
solid
howev
composit
may
chang
variou
patholog
condit
site
variat
mucu
layer
within
pulmonari
tract
import
evolutionari
trait
support
function
variou
site
mucu
thick
increas
distal
proxim
part
pulmonari
tract
partli
consequ
mucociliari
escal
mechan
primari
innat
defens
mechan
airway
serv
purpos
remov
foreign
particl
lung
mechan
combin
two
effect
particl
entrap
mucu
layer
remov
shed
layer
mucu
ciliari
movement
estim
rate
clearanc
mmmin
cough
anoth
clearanc
mechan
mucu
move
airway
way
mucu
build
proxim
part
airway
thick
trachea
mucu
reach
pharynx
clear
gastrointestin
tract
protect
properti
mucu
pose
barrier
rnaibas
therapeut
nake
within
deliveri
system
nanoparticl
two
approach
govern
design
particl
mucos
deliveri
mucoadhes
mucu
penetr
mucoadhes
achiev
use
mucoadhes
polym
chitosan
prolong
bioavail
particl
mucos
surfac
materi
nanoparticl
may
alter
structur
mucu
becom
permeabl
sirnaload
particl
mucuspenetr
particl
limit
interact
mucu
increas
diffus
rate
achiev
pegyl
excit
approach
overcom
mucos
barrier
periciliari
liquid
layer
space
mucu
layer
apic
side
epithelia
approxim
height
larger
airway
correspond
length
cilia
decreas
height
airway
get
smaller
height
periciliari
liquid
layer
togeth
viscos
mucu
layer
determin
effect
mucu
remov
alveoli
devoid
mucu
instead
line
surfact
enabl
expand
intrigu
abil
mucu
entrap
foreign
pathogen
facilit
activ
clearanc
pathogen
respiratori
tract
crucial
surviv
time
repres
biggest
hurdl
sirnabas
treatment
explor
respiratori
rout
administr
commonli
accept
sirna
need
administ
togeth
deliveri
system
pulmonari
deliveri
even
though
nake
sirna
shown
therapeut
effect
undergon
sever
clinic
trial
studi
glud
et
al
nake
sirna
modifi
lock
nucleic
acid
lna
administ
intraven
inject
five
dose
show
reduct
enhanc
green
fluoresc
protein
egfp
express
bronchoepitheli
cell
transgen
egfp
mous
author
attribut
effect
greater
serum
stabil
modifi
sirna
incorpor
sirna
within
nanoparticl
compos
polyc
term
polyplex
shown
induc
pulmonari
silenc
intraven
administr
polyplex
system
base
polyc
polyethylenimin
pei
use
antiinfluenza
effect
preclin
studi
ge
et
al
use
intraven
rout
administr
retroorbit
inject
peisirna
complex
influenza
nucleocapsid
protein
andor
influenza
rna
transcriptas
compon
pa
mice
prophylact
treatment
sirna
singl
dose
induc
reduct
viral
titer
day
postinfect
compar
nontreat
mice
therapeut
approach
peisirna
complex
sirna
singl
dose
also
show
reduct
viral
titer
administ
h
infect
similar
studi
thoma
et
al
show
reduct
viral
titer
prophylact
retroorbit
administr
peisirna
complex
influenza
nucleocapsid
protein
use
highli
deacetyl
pei
accumul
system
lung
may
reflect
seruminduc
aggreg
consequ
entrap
lung
capillari
bed
observ
peidna
complex
possibl
lung
embol
result
capillari
entrap
would
seemingli
restrict
likelihood
clinic
translat
approach
contrast
use
peisirna
complex
tompkin
et
al
investig
antivir
properti
nake
sirna
influenza
nucleocapsid
protein
andor
acid
polymeras
intraven
inject
prophylact
treatment
sirna
singl
dose
follow
intranas
administr
cation
lipidbas
sirna
formul
sirna
singl
dose
simultan
viral
infect
analyz
titer
day
postchalleng
approxim
reduct
viral
titer
observ
specif
rnaibas
antivir
effect
question
robbin
et
al
base
immun
stimul
egfp
sequenc
employ
neg
control
author
suggest
observ
therapeut
effect
report
earli
studi
like
due
activ
innat
immun
respons
recognit
viralspecif
nonmodifi
sirna
sequenc
tolllik
receptor
tlr
instead
rnaimedi
effect
robbin
et
al
found
egfp
sequenc
use
neg
control
howev
induc
innat
immun
respons
emphas
import
design
sirna
sequenc
possibl
activ
innat
immun
respons
caus
secondari
effect
evalu
sirnabas
therapeut
describ
thoroughli
activ
immun
system
seruminduc
aggreg
decreas
introduc
hydrophil
polym
polyplex
surfac
recent
studi
ghosn
et
al
reduct
lung
gapdh
express
intraven
administr
pegyl
complex
nonmodifi
sirna
demonstr
reduct
gapdh
lung
protein
level
highlight
potenti
polyplex
target
pulmonari
diseas
reduct
also
observ
liver
show
nonspecif
accumul
associ
system
administr
surfac
modif
inclus
hydrophil
polym
might
reduc
possibl
seruminduc
aggreg
howev
deposit
lung
may
compromis
lipoplex
base
cation
lipid
complex
sirna
altern
polyplex
gene
silenc
lung
gutbier
et
al
use
lipoplex
atuplex
complex
sirna
endotheli
vecadherin
report
reduct
mrna
level
pulmonari
vascular
endotheli
cell
intraven
inject
nonmodifi
sirna
singl
dose
per
day
four
consecut
day
pulmonari
gene
silenc
demonstr
use
chitosan
studi
use
chitosanbas
polyplex
system
form
cation
chitosan
anion
sirna
chitosan
natur
polysaccharid
compris
link
glucosamin
nacetyl
glucosamin
deriv
partial
deacetyl
chitin
present
shell
crustacean
bacteri
wall
insect
exoskeleton
mushroom
biomateri
biodegrad
biocompat
mucoadhes
facilit
mucoperm
chitosanbas
sirna
deliveri
system
develop
group
interdisciplinari
nanosci
center
inano
aarhu
univers
shown
effect
silenc
egfp
transgen
egfp
mice
nasal
administr
chitosanegfp
sirna
nanoparticl
sirna
per
day
day
show
reduct
egfp
bronchoepitheli
cell
compar
untreat
mice
later
studi
confirm
silenc
potenti
chitosanegfp
sirna
system
intranas
administr
transgen
egfp
mice
knockdown
egfp
observ
bronchoepitheli
cell
despit
encourag
result
intranas
administr
may
restrict
transit
lung
due
possibl
nasal
adher
partial
gastrointestin
clearanc
lower
amount
reach
pulmonari
target
altern
method
use
intratrach
instil
aerosol
exploit
gaseou
exchang
function
lung
improv
deposit
airway
clinic
perspect
aerosolizedbas
deliveri
inhal
expect
predomin
choic
subsequ
studi
use
chitosansirna
system
group
demonstr
egfp
silenc
aerosol
chitosan
particl
formul
produc
nebul
cathet
trudel
medic
instrument
directli
insert
trachea
egfp
mice
observ
deposit
chitosansirna
conduct
respiratori
airway
epithelium
addit
egfp
knockdown
compar
mismatch
observ
flow
cytometr
analysi
use
low
amount
sirna
per
dose
three
dose
pei
also
use
deliveri
system
pulmonari
administr
although
interact
properti
pei
mucu
investig
earli
studi
merkel
et
al
polyplex
target
egfp
administ
intratrach
instil
cagegfp
mice
egfp
sirna
singl
dose
knockdown
egfp
evalu
day
postadministr
egfp
found
reduc
lung
compar
mice
receiv
nonspecif
luciferas
sirna
later
studi
beyerl
et
al
administ
fatti
acidmodifi
complex
intratrach
instil
mice
observ
reduct
egfp
compar
nontreat
anim
sirna
singl
dose
pegyl
polyplex
show
reduc
cytotox
effect
increas
secret
proinflammatori
cytokin
observ
merkel
et
al
similarli
found
induct
sever
proinflammatori
cytokin
acut
cytokin
respons
togeth
granulocyt
coloni
stimul
factor
induc
protein
bronchoalveolar
lavag
fluid
administr
pegyl
polyplex
induct
immun
respons
howev
overcom
chemic
modif
sirna
see
clinic
translat
altern
deliveri
system
use
pulmonari
gene
silenc
includ
pulmonari
surfact
infasurf
genzym
cholesterol
cellpenetr
peptid
tat
penetratin
intranas
instil
singl
dose
surfact
mix
antigapdh
sirna
result
knockdown
protein
level
lung
h
day
respect
postadministr
mice
reduct
gapdh
also
observ
heart
h
kidney
h
indic
degre
system
dissemin
contrast
find
griesenbach
et
al
use
cation
lipid
genzym
commonli
use
vivo
gene
transfer
intranas
administr
complex
result
uptak
alveolar
macrophag
h
detect
uptak
airway
epithelia
reduct
mrna
observ
airway
epithelia
express
transgen
mice
h
without
detect
reduct
protein
level
import
factor
success
epitheli
uptak
timescal
complex
contact
mucos
line
attempt
prolong
period
griesenbach
et
al
slowli
perfus
lipidsirna
sirna
nostril
mice
min
howev
uptak
observ
nasal
epithelia
h
perfus
cellpenetr
peptid
repres
altern
deliveri
method
studi
moscho
et
al
sirna
map
kinas
conjug
cholesterol
tat
penetratin
biolog
effect
vivo
examin
intratrach
administr
mice
administr
linkermodifi
sirna
alon
show
distribut
macrophag
epitheli
cell
reduct
map
kinas
mrna
h
depend
dose
nmol
nonmodifi
sirna
effect
observ
transient
dose
result
knockdown
h
h
sirna
conjug
cholesterol
knockdown
durat
prolong
h
h
conjug
sirna
cellpenetr
peptid
tat
result
knockdown
map
kinas
mrna
compar
linkermodifi
sirna
intratrach
administr
wherea
conjug
penetratin
result
slightli
increas
knockdown
h
notic
peptid
caus
reduc
gene
express
administ
alon
indic
modul
effect
peptid
map
express
activ
innat
immun
respons
penetr
sirna
nasal
pulmonari
deliveri
nonmodifi
sirna
either
nake
within
deliveri
system
result
reduct
diseas
state
pulmonari
fibrosi
ischemia
reperfus
injuri
acut
lung
injuri
tuberculosi
equin
herp
lung
metastas
sar
coronaviru
follow
section
howev
focu
preclin
evalu
antirsv
rnaibas
therapi
due
translat
clinic
trial
antirsv
studi
evalu
wellestablish
murin
model
balbc
mice
local
administ
therapeut
approxim
h
viral
inocul
subsequ
viral
analysi
carri
day
postinfect
pioneer
preclin
studi
treatment
rsv
use
sirna
perform
bitko
et
al
show
intranas
administr
rsv
sirna
either
complex
commerci
transittko
reagent
nake
nonmodifi
sirna
per
dose
one
dose
reduc
viral
titer
sever
log
effect
highest
complex
sirna
interestingli
nake
sirna
also
show
substanti
reduct
estim
compar
transittko
complex
sirna
observ
equal
reduct
viral
titer
sirna
administr
rsv
infect
relev
design
relev
treatment
strategi
administr
sirna
later
stage
show
reduct
compar
nontreat
effect
significantli
reduc
author
suggest
cur
effect
sirna
would
import
goal
pediatr
medicin
follow
find
zhang
tripp
show
prophylact
instil
sirna
protein
p
rsv
decreas
viral
titer
without
limit
induct
memori
immun
respons
anoth
studi
zhang
et
al
administ
plasmidclon
sirna
rsv
nonstructur
protein
complex
chitosan
intranas
mice
one
dose
g
plasmid
observ
reduct
viral
titer
complex
administ
viral
inocul
protect
effect
last
day
protect
effect
partial
enhanc
increas
ifnmedi
immun
suggest
author
possibl
result
downregul
antagon
ifn
respons
similarli
kong
et
al
use
plasmid
encod
sirna
rsv
protein
within
chitosan
deliveri
system
intranas
deliveri
fischer
rat
h
prior
infect
rsv
show
reduct
viral
titer
observ
day
later
plasmid
encod
sirna
sequenc
howev
allow
possibl
instal
chemic
modif
control
dose
synthet
sirna
alnylam
pharmaceut
wwwalnylamcom
use
antirsv
sirna
shown
promis
effect
prophylact
balbc
model
rsv
infect
nake
intranas
administr
prophylact
treatment
singl
dose
show
dosedepend
reduct
viral
titer
sirna
log
reduct
sirna
log
reduct
sirna
log
reduct
singl
dose
sirna
reduc
titer
background
level
follow
administr
singl
dose
day
postinfect
effect
decreas
increas
time
infect
multipl
daili
dose
sirna
per
dose
three
time
daili
howev
reduc
viral
titer
level
singl
dose
specif
sirna
sequenc
rsv
taken
clinic
trial
repres
one
advanc
sirnabas
therapeut
refer
rsv
clinic
program
observ
therapeut
effect
intranas
administr
nake
sirna
contradictori
common
percept
anion
macromolecular
characterist
sirna
reduc
cellular
interact
uptak
therefor
requir
deliveri
system
loss
cellular
integr
infect
cellular
receptor
doublestrand
rna
could
possibl
explain
mechan
cellular
intern
nake
antirsv
sirna
preclin
studi
use
nonmodifi
sirna
may
activ
innat
immun
respons
lead
advers
effect
therefor
import
clinic
translat
understand
address
potenti
advers
effect
solut
avoid
tlr
pattern
recognit
receptor
express
cell
andor
endosom
membran
ten
human
tlr
identifi
relev
sirna
therapeut
express
cell
surfac
endosom
particip
cellular
antivir
respons
detect
sequenceindepend
manner
dsrna
replic
intermedi
genom
mani
rna
virus
activ
result
type
interferon
product
consequ
induct
repress
ifnregul
gene
involv
variou
cellular
activ
apoptosi
antivir
antiprolif
respons
fact
antiangiogen
result
observ
patient
neovascular
form
agerel
macular
degener
sever
clinic
trial
employ
rnaibas
therapeut
may
probabl
attribut
engag
specif
silenc
intend
target
reason
specul
case
chemic
modif
sirna
may
abl
suppress
immun
recognit
local
exclus
endosom
detect
nucleic
acid
deriv
intern
lyse
microb
receptor
involv
antivir
immun
respons
detect
sequencedepend
manner
ssrna
probabl
duplex
rna
sequenc
requisit
fulli
establish
although
uridin
u
guanosin
g
rich
sequenc
particularli
present
ugu
ug
motiv
seem
trigger
activ
addit
also
detect
adenosin
uridin
au
rich
sequenc
seem
howev
factor
dsrna
length
may
influenc
respons
agreement
stimulatori
motif
guccuucaa
induc
consider
less
cytokin
product
includ
nt
sirna
compar
nt
sequenc
interestingli
multipl
uridin
close
proxim
ribos
backbon
may
suffici
sequenceindepend
manner
stimul
sirna
theoret
stimulatori
u
grich
characterist
fail
induc
potent
immun
respons
addit
tlr
cell
possess
certain
cytosol
protein
act
sensor
viral
infect
shown
interact
rnai
effector
molecul
protein
kinas
r
pkr
tradit
consid
main
cytoplasm
sensor
viral
dsrna
interact
sequenceindepend
manner
facilit
format
homodim
consequ
activ
protein
autophosphoryl
although
bp
consid
lower
length
level
rna
recognit
recent
studi
suggest
bp
sirna
may
also
bind
extent
mediat
pkr
activ
significantli
sirna
blunt
classic
nucleotid
termin
overhang
may
suscept
recognit
uncertain
howev
extent
interact
result
translat
inhibit
phosphoryl
induct
proinflammatori
cytokin
ifnregul
gene
respons
normal
attribut
activ
case
chemic
modif
sirna
effect
use
avoid
pkr
recognit
current
rigilik
receptor
rigi
consid
main
cytoplasm
sensor
viral
dsrna
retinoidinduc
gene
rigi
particular
relev
develop
rnai
therapeut
activ
short
rna
fragment
rigi
normal
involv
foreign
rna
recognit
detect
uncap
structur
shown
certain
situat
mediat
sirnatrigg
immun
respons
bluntend
sirna
appear
induc
rigi
activ
manner
proport
dsrna
length
suggest
benefit
stagger
end
avoid
recognit
becom
evid
satur
rnai
machineri
exogen
rnai
trigger
may
induc
seriou
detriment
effect
alter
mirna
activ
disturb
first
suggest
studi
employ
short
hairpin
rna
shrna
stemloop
effector
molecul
normal
transcrib
plasmid
viral
vector
compet
exportin
nucleocytoplasm
transport
factor
requir
mirna
nuclear
export
shrna
potenti
disrupt
mirna
activ
lead
cellular
toxic
even
lethal
phenotyp
mice
studi
grimm
et
al
longterm
effect
high
shrna
express
liver
adult
mice
evalu
intraven
infus
adenoassoci
virusbas
shrna
vector
screen
shrna
hepat
overexpress
caus
dosedepend
toxic
could
attribut
restrict
mirna
activ
nearli
half
case
shrna
anim
mortal
observ
within
month
addit
cotransfect
studi
multipl
sirna
shown
reduc
individu
efficaci
effector
molecul
suggest
competit
silenc
machineri
fact
competit
seem
also
affect
mirna
activ
demonstr
recent
studi
increas
express
gene
target
common
mirna
observ
upon
sirna
transfect
result
highlight
import
ensur
appropri
shrna
express
level
care
vector
design
optim
sirna
dosag
achiev
desir
gene
silenc
without
disrupt
mirna
function
mirnalik
offtarget
effect
defin
unintent
downregul
gene
express
manner
resembl
mirna
translat
blockag
specif
offtarget
activ
mediat
perfect
match
anneal
sirna
seed
sequenc
posit
terminu
guid
strand
utr
mrna
although
mrna
share
sequenc
complementari
utr
sirna
seed
sequenc
would
affect
process
activ
could
potenti
compromis
express
hundr
gene
sirna
strand
potenti
serv
guid
strand
differ
strategi
develop
avoid
rnai
activ
incorpor
activ
risc
undesir
sirna
strand
gener
strand
select
determin
thermodynam
stabil
sirna
end
nonguid
strand
stabl
terminu
term
base
pair
therefor
differ
chemic
modif
increas
lna
substitut
decreas
unlock
nucleic
acid
una
thiophosph
modif
base
pare
stabil
introduc
achiev
appropri
thermodynam
asymmetri
sirna
end
reduc
particip
undesir
strand
also
accomplish
use
effector
molecul
strand
present
insuffici
length
intern
segment
altern
strand
render
inact
avoid
presenc
termin
phosphat
group
requir
activ
achiev
inhibit
phosphoryl
strand
normal
cellular
process
placement
termin
una
addit
ensur
appropri
strand
select
chemic
modif
guid
strand
includ
abolish
mirnalik
activ
exampl
substitut
posit
count
terminu
shown
reduc
offtarget
transcript
without
loss
ontarget
activ
similarli
reduc
offtarget
observ
substitut
dna
entir
seed
sequenc
introduct
una
posit
alnylam
pharmaceut
partnership
kyowa
hakko
kirin
cubist
pharmaceut
rsv
program
current
phase
iib
tabl
clinic
trial
evalu
safeti
pharmacokinet
activ
nake
nonmodifi
sirna
administ
without
deliveri
vehicl
respiratori
tract
compos
classic
sirna
design
select
preclin
studi
base
high
antivir
activ
broad
spectrum
across
rsv
strain
low
homolog
human
genom
abil
target
viral
nprotein
gene
one
conserv
region
rsv
genom
first
phase
studi
involv
healthi
male
salin
placebo
administr
nasal
spray
bectondickinson
accuspraytm
singledos
arm
studi
noplacebo
subject
expos
mg
multipledos
arm
cohort
receiv
daili
dose
mg
sirna
period
day
followup
evalu
symptom
object
sign
reveal
transient
mild
moder
advers
effect
occur
similar
frequenc
sever
placebo
group
interestingli
pharmacokinet
analys
reveal
individu
sirna
could
detect
sever
blood
sampl
first
h
administr
urin
h
postdos
subsequ
phase
clinic
trial
investig
inhal
deliveri
sirna
studi
present
annual
drug
deliveri
lung
meet
held
edinburgh
uk
includ
subject
receiv
salin
receiv
either
mgkg
daili
day
mgkg
dose
inhal
use
nebul
system
pari
pharma
consid
safe
well
toler
healthi
adult
mild
moder
flulik
advers
event
observ
higher
dose
mgkg
daili
administr
mgkg
day
found
well
toler
smaller
amount
sirna
administ
part
multidos
strategi
may
permit
high
antivir
activ
without
potenti
advers
event
associ
larg
singl
dose
order
assess
prophylact
therapeut
activ
infect
subject
alnylam
collabor
meridian
life
scienc
sever
univers
research
center
develop
highli
reproduc
human
experiment
infect
model
intranas
inocul
healthi
male
femal
infecti
wildtyp
rsv
memphi
strain
allow
studi
quantit
tempor
correl
viral
load
diseas
progressionsever
furthermor
data
suggest
aberr
immun
respons
trigger
viru
appear
drive
diseas
manifest
human
contrast
anim
establish
model
allow
compani
move
phase
ii
clinic
trial
experiment
infect
adult
treat
day
day
rsv
inocul
studi
refer
gemini
aim
evalu
safeti
toler
demonstr
first
time
proofofconcept
antivir
activ
sirna
human
exhibit
safeti
profil
similar
salin
administr
induc
mild
moder
upper
respiratori
tract
ill
sirna
administr
nasal
spray
bectondickinson
accuspraytm
result
rel
reduct
number
infect
increas
number
uninfect
subject
compar
placebo
control
antivir
effect
statist
signific
subject
receiv
highest
daili
dose
mg
lower
dose
mg
administr
probabl
due
small
number
subject
group
preclin
studi
demonstr
specif
rnai
effect
base
identif
nprotein
mrna
cleav
product
demonstr
antivir
activ
immunesil
version
lack
effect
unrel
sirna
immunestimulatori
properti
antivir
activ
report
gemini
studi
independ
intranas
cytokin
level
suggest
neglig
contribut
immun
stimul
due
necess
reach
higher
lower
respiratori
tract
nebul
system
pari
pharma
employ
phase
iia
studi
conduct
rsvinfect
lung
transplant
patient
immunecompromis
popul
rsv
infect
associ
seriou
complic
increas
mortal
studi
subject
receiv
inhal
placebo
mgkg
dose
daili
three
consecut
day
dose
regim
previous
demonstr
well
toler
healthi
individu
agreement
previou
observ
drugrel
seriou
advers
event
detect
lung
transplant
patient
studi
achiev
primari
object
demonstr
safeti
toler
inhal
natur
infect
individu
although
studi
demonstr
statist
signific
antivir
effect
promis
find
observ
regard
incid
new
progress
bronchiol
obliteran
syndrom
bo
bo
progress
inflammatori
lesion
associ
irrevers
loss
respiratori
function
lung
transplant
patient
link
organ
reject
increas
posttranspl
mortal
rel
placebo
group
subject
treat
present
lower
incid
seriou
patholog
addit
lower
daili
symptom
score
period
report
symptom
includ
exampl
sneez
sore
throat
cough
short
breath
myalgia
pleurit
chest
pain
secondari
endpoint
viral
load
reduct
shorter
durat
viral
shed
could
achiev
although
imbal
viral
load
baselin
placebo
cohort
reduc
number
subject
studi
may
reason
observ
recent
alnylam
announc
toplin
result
new
clinic
trial
rsvinfect
lung
transplant
patient
treat
phase
iib
trial
addit
data
would
disclos
septemb
enrol
patient
split
equal
drug
placebo
group
owe
imposs
confirm
rsv
infect
patent
socal
lab
confirm
ittc
analysi
popul
includ
patient
treat
placebo
treat
primari
endpoint
clinic
trial
investig
bo
incid
day
postrsv
infect
although
reduct
bo
incid
observ
group
compar
placebo
clinic
relev
data
narrowli
miss
statist
signific
ittc
analysi
popul
p
howev
sirna
treatment
associ
statist
signific
reduct
bo
incid
prospect
defin
analys
ittc
patient
last
observ
carri
forward
p
ittc
patient
treat
per
protocol
p
studi
placebo
mgkg
dose
administr
nebul
system
pari
pharma
daili
five
consecut
day
overal
treatment
toler
although
subject
placebo
group
develop
seriou
treatment
emerg
advers
event
length
studi
three
particip
die
due
unrel
caus
treatment
alnylam
announc
intent
discuss
result
us
eu
regulatori
author
order
determin
appropri
step
clinic
implement
potenti
har
rnai
pathway
potent
therapeut
fuel
numer
preclin
investig
attract
enorm
interest
invest
big
pharma
clinic
translat
howev
depend
high
efficaci
safeti
costeffect
lesson
learnt
earli
rnai
studi
emphas
necess
optim
rnai
molecul
design
reduc
induct
innat
immun
respons
maxim
target
specif
furthermor
deliveri
technolog
consid
key
realiz
full
clinic
potenti
wide
rang
nanoparticlebas
deliveri
system
develop
howev
complex
design
requir
pegyl
target
need
overcom
system
barrier
facilit
sitespecif
deliveri
associ
high
product
cost
would
seemingli
restrict
clinic
util
system
short
term
altern
approach
mucos
rnai
therapi
base
direct
applic
diseas
site
respiratori
tract
diseas
ideal
candid
approach
particular
acut
viral
infect
suscept
transient
rnai
activ
furthermor
target
conserv
viral
gene
cellular
host
factor
may
limit
viral
escap
avoid
necess
season
vaccin
mucos
barrier
need
breach
deliveri
requir
less
complex
exemplifi
success
alnylam
nake
sirna
seem
like
howev
deliveri
system
requir
potenti
deliveri
across
mucos
surfac
albeit
simpl
design
attract
clinic
implement
major
respiratori
studi
focus
rnaibas
pulmonari
diseas
treatment
howev
like
focu
direct
toward
nasal
diseas
due
greater
access
import
consider
clinic
translat
cost
puriti
sirna
commerci
largescal
high
qualiti
hplc
grade
endotoxinfre
materi
present
purchas
g
addit
fda
requir
current
good
manufactur
practic
materi
human
use
would
increas
cost
rel
low
dose
use
rsv
clinic
trial
continu
reduct
sirna
product
cost
howev
suggest
feasibl
applic
drug
work
outlin
mucos
barrier
deliveri
solut
optim
sirna
design
preclin
evalu
essenti
step
clinic
translat
respiratori
rnaibas
therapi
